Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in type 2 diabetes

Clinical Science

Volumn 115, Issue 11, 2008, Pages 327-334

  Suguro, Toshiaki ^a   Watanabe, Takuya ^a   Kodate, Syuusuke ^a   Xu, Gang ^a   Hirano, Tsutomu ^a   Adachi, Mitsuru ^a   Miyazaki, Akira ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Carotid atherosclerosis; Diabetic retinopathy; Type 2 diabetes; Urotensin II; Vascular endothelial growth factor (VEGF)

Indexed keywords

HEMOGLOBIN A1C; HEREGULIN BETA1; LOW DENSITY LIPOPROTEIN; NEU DIFFERENTIATION FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UROTENSIN II; VASCULOTROPIN; BIOLOGICAL MARKER; UROTENSIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ALCOHOL CONSUMPTION; ANGIOGENESIS; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; EYE FUNDUS; FEMALE; GENETIC CODE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INTIMA; JAPANESE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PULSE WAVE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STATISTICAL SIGNIFICANCE; AGED; BLOOD; CAROTID ARTERY DISEASE; DIABETIC ANGIOPATHY; ECHOGRAPHY; EPIDEMIOLOGY; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; UROTENSINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149143172     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080014     Document Type: Article

References (52)

1. Ames, R. S., Sarau, H. M., Cambers, J. K. et al. (1999) Human urotensin II is a potent vasoconstrictor and agoni for the orphan receptor GPR14. Nature 401, 282-286
2. Watson, A. M. D., Lambert, G. W., Smith, K. J. and May, C. N. (2003) Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42, 373-379
3. Silvestre, R. A., Egido, E. M., Hernandez, R. et al. (2004) Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur. J. Endocrinol. 151, 803-809
4. Maguire, J. J., Kuc, R. E., Kleinz, M. J. and Davenport, A. P. (2008) Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function. Peptides 29, 735-742
5. Charles, C. J., Rademaker, M. T., Richards, A. M. and Yandle, T. G. (2005) Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 26, 2211-2114
6. Watanabe, T., Kanome, T., Miyazaki, A. and Katagiri, T. (2006) Human urotensin II linking hypertension and coronary artery disease. Hypertens. Res. 29, 375-387
7. Suguro, T., Watanabe, T., Ban, Y. et al. (2007) Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am.J.Hypertens. 20, 211-217
8. Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Ito, S. and Murakami, O. (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. 104, 1-5
9. Suzuki, S., Wenyi, Z., Hirai, M., et al. (2004) Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japaneses. Peptides 25,1803-1808
10. Sidharta, P. N., Wagner, F. D., Bohnemeier, H. et al. (2006) Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in microalbuminuric, diabetic patients. Clin. Pharmacol. Ther. 80, 246-256
11. Langham, R. G., Kelly, D. G., Gow, R. M. et al. (2004) Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am. J. Kidney Dis. 44, 826-831
12. Bousette, N., Patel, L., Douglas, S. A., Ohlstein, E. H. and Giaid, A. (2004) Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176, 117-123
13. Watanabe, T., Suguro, T., Kanome, T. et al. (2005) Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46, 738-744
14. Watanabe, T., Pakala, R., Katagiri, T. and Benedict, C. R. (2001) Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J. Hypertens. 19, 2191-2196
15. Watanabe, T., Pakala, R., Katagiri, T. and Benedict, C. R. (2001) Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104, 16-18
16. Shi, L., Ding, W., Li, D. et al. (2006) Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188, 260-264
17. Gendron, G., Simard, B., Gobeil, Jr, F., Sirois, P., D'Orleans-Juste, P. and Regoli, D. (2004) Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats. Can. J. Physiol. Pharmacol. 82,16-21
18. Matsusaka, S. and Wakabayashi, I. (2006) Enhancement of vascular smooth muscle cell migration by urotensin II. Naunyn. Schmiedebergs Arch. Pharmacol. 373, 381-386
19. Tzanidis, A., Hannan, R. D., Thomas, W. G. et al. (2003) Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res. 93, 246-253
20. Spinazzi, R., Albertin, G., Nico, B. et al. (2006) Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. Int. J. Mol. Med. 18, 1107-1112
21. Kim, N. H., Kim, K. B., Kim, D. L. et al. (2004) Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabetic Med. 21 , 545-551
22. Yen, L., You, X. L., Al Moustafa, A. E. et al. (2000) Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19, 3460-3469
23. Gold, S. J., Thompson, J. P., Williams, J. P. et al. (2007) Does cigarette smoking increase plasma urotensin II concentrations? Eur. J. Clin. Pharmacol. 63, 253-257
24. Davis, M. D., Myers, F. L., Bresnick, G. H. et al. (1977) Natural evolution. In Current Diagnosis and Management of Chorio-Retinal Diseases (L'Esperance, Jr, F.A., ed.), pp. 179-184, Mosby, St. Louis
25. Hirano, T., Sakaue, T., Misaki, A. et al. (2003) Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apolipoprotein CIII. Kidney Int. 63, 2171-2177
26. Duh, E. and Aiello, L. P. (1999) Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48, 1899-1906
27. Tolentino, M. J., Miller, J. W., Gragoudas, E. S. et al. (1996) Intravenous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103, 1820-1828
28. Alon, T., Hemo, I., Itin, A. et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1, 1024-1028
29. Gerber, H. P., Hillan, K. J., Ryan, A. M. et al. (1999) VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159
30. Russell, K. S., Stern, D. F., Polverini, P. J. and Bender, J. R. (1999) Neuregulin activation of Erb receptors in vascular endothelium leads to angiogenesis. Am. J. Physiol. 46, H2205-H2211
31. Panutsopulos, D., Arvanitis, D. L., Tsatsanis, C., Papalambros, E., Sigala, F. and Spandidos, D. A. (2005) Expression of heregulin in human coronary atherosclerotic lesions. J. Vasc. Res. 42, 463-474
32. Sigala, F., Georgopoulos, S., Papalambros, E. et al. (2006) Heregulin, cysteine rich-61 and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with clinical data. Eur. J. Vasc. Endovasc. Surg. 32,238-245
33. Clement, C. M., Thomas, L. R., Mou, Y., Croslan, D. R., Gibbons, G. H. and Ford, B. D. (2007) Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J. Vasc. Res. 44, 303-312
34. Yamagishi, S. and Imaizumi, T. (2005) Diabetic vascular omplications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11, 2279-2299
35. Wang, H., Mehta, J. L., Chen, K., Zhang, X. and Li, D. (2004) Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J. Cardiovasc. Pharmacol. 44, 577-581
36. Djordjevic, T., BelAiba, R. S., Bonello, S., Pfeilschifter, J., Hess, J. and Gorlach, A. (2005) Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 25, 519-525
37. Wang, Y. X., Ding, Y. J., Zhu, Y. Z., Shi, Y., Yao, T. and Zhu, Y. C. (2007) Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am. J. Physiol. Heart Circ. Physiol. 292, H348-H359
38. Watanabe, T., Takahashi, K., Kanome, T. et al. (2006) Human urotensin-II potentiates mildly oxidized LDL-induced vascular smooth muscle cell proliferation: comparison with other vasoactive agents and hydrogen peroxide. Hypertens. Res. 29, 821-831
39. Totsune, K., Takahashi, K., Arihara, Z. et al. (2004) Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25, 1809-1814
40. Heringlake, M., Kox, T., Uzun, O. et al. (2004) The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul. Pept. 121,129-136
41. Hassan, G. S., Douglas, S. A., Ohlstein, E. H. and Giaid, A. (2005) Expression of urotensin-II in human coronary atherosclerosis. Peptides 26, 2464-2472
42. Segain, J. P., Rolli-Derkinderen, M., Gervois, N., Raingeard de la Blétière, D., Loirand, G. and Pacaud, P. (2007) Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J. Immunol. 179,901-909
43. Birker-Robaczewska, M., Boukhadra, C., Studer, R., Mueller, C., Binkert, C. and Nayler, O. (2003) The expression of urotensin II receptor (U2R) is up-regulated by interferon-γ .J. Recept. Signal Transduct. Res. 23, 289-305
44. Hongfang, J., Bailin, C., Bin, Z. et al. (2006) Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci. 78,1299-1309
45. Rakowski, E., Hassan, G. S., Dhanak, D., Ohlstein, E. H., Douglas, S. A. and Giaid, A. (2005) A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J. Mol. Cell. Cardiol. 39, 785-791
46. Dschietzig, T., Richter, C., Bartsch, C. et al. (2001) Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. Biochem. Biophys. Res. Commun. 289, 245-251
47. Dhanak, D., Neeb, M. J. and Douglas, S. A. (2003) Urotensin-II receptor modulators. Annu. Rep. Med. Chem. 38, 99-110
48. Shiraishi, Y., Watanabe, T., Suguro, T. et al. (2008) Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. J. Hypertens. 26, 1955-1965
49. Douglas, S. A. (2003) Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr. Opin. Pharmacol. 3,159-167
50. Kang, S., Wu, Y. and Li, X. (2004) Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 177, 433-442
51. Mortsell, D., Malmqvist, K., Held, C. and Kahan, T (2007) Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J. Intern. Med. 261, 472-479
52. Uchiyama-Tanaka, Y., Mori, Y., Kishimoto, N. et al. (2005) Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney Blood Press. Res. 28,111-116